Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2004

View Archived Issues

Farnesoid X receptor agonist protects against liver fibrosis

JTE-607 induces cardioprotective effects in a rat model of ischemia and reperfusion

Once-daily mosapride improves constipation in PD patients

Botulinum toxin A shows promise in the treatment of detrusor overactivity

Good efficacy and safety profile found for XP-828L in mild to moderate psoriasis

Novel COX-1 inhibitors prepared and tested at Fujisawa

Novel PPARdelta agonists identified by Bayer researchers

Clinical data support the use of gemifloxacin in AECB

New NO-donating rapamycin derivatives described by NitroMed

Vertex claims new SHP-2 phosphatase inhibitors and their use

Novel aggrecanase/MMP-13 inhibitors under study at Japan Tobacco

Janssen researchers present new PAR-1 antagonists

New cannabinoid CB1/CB2 ligands and their use claimed by AstraZeneca

Potential use of a kappa opioid agonist in abdominal pain of IBS

Neramexane fails to reach statistical significance in phase III Alzheimer's study

NRP-104 given fast track status for treating cocaine dependence

Micrologix Biotech completes acquisition of MitoKor

Chiron acquires Prion Solutions

Satraplatin plus radiation therapy studies in phase I/II trial for NSCLC

Exenatide NDA accepted for review

MGI Pharma to acquire Zycos

MGI Pharma signs definitive merger agreement to acquire Aesgen

MGI Pharma and SuperGen sign license agreement for Dacogen

Positive interim results from phase II trials of TroVax

NDA submission for Aczone

Procleix WNV Assay tested on Procleix TIGRIS System under IND

GlaxoSmithKline acquires Fraxiparine, Fraxodi and Arixtra

Celsion cleared to conduct phase I study of ThermoDox in liver cancer

Clarinex syrup approved for use in children with allergies, hives

Antithrombotic effects of novel coagulation factor Xa inhibitor

Lethal factor inhibitor effective in anthrax infection

Dual protease inhibitor effective against inflammatory processes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.